MBX Biosciences, Inc. (MBX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, MBX Biosciences reported revenue of $0. Net income was -$87.0M, or -$2.38 per diluted share. Operating activities generated -$79.9M of cash, leaving -$81.9M of free cash flow. At fiscal year end, MBX Biosciences held $385.1M in total assets against $15.9M in total liabilities, including $75.3M of cash and equivalents.
Open the full interactive MBX Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
MBX Biosciences Key Stats
| Share Price | $49.00 |
|---|---|
| Market Cap | $2.34B |
| 52-Week Range | $13.22 – $70.70 |
| Shares Outstanding | 47.7 million (basic, 2026 Q2) |
MBX Biosciences Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Income | -$68.2M | -$98.1M |
| Pre-Tax Income | -$61.9M | -$87.0M |
| Income Tax | $0 | $0 |
| Net Income | -$61.9M | -$87.0M |
| Diluted EPS | -$5.82 | -$2.38 |
MBX Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$21.6M | -$22.1M | -$23.5M | -$37.1M |
| Diluted EPS | -$0.63 | -$0.60 | -$0.50 | -$0.78 |
MBX Biosciences Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $49.4M | $75.3M |
| Current Assets | $267.3M | $381.5M |
| Total Assets | $268.5M | $385.1M |
| Current Liabilities | $11.1M | $15.5M |
| Total Liabilities | $11.1M | $15.9M |
| Shareholders' Equity | $257.4M | $369.2M |
MBX Biosciences Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$54.7M | -$79.9M |
| Cash From Investing | -$160.6M | -$83.7M |
| Cash From Financing | $234.1M | $189.6M |
| Free Cash Flow | -$55.6M | -$81.9M |
Figures from MBX Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full MBX Biosciences financials page for every line item.
MBX Biosciences Company Profile
| Ticker | MBX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Carmel, Indiana |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001776111 |
Frequently Asked Questions
What was MBX Biosciences' revenue in fiscal 2025?
MBX Biosciences (MBX) reported revenue of $0 for fiscal 2025.
What was MBX Biosciences' net income in fiscal 2025?
MBX Biosciences reported net income of -$87.0M for fiscal 2025.
What was MBX Biosciences' earnings per share (EPS) in fiscal 2025?
MBX Biosciences' diluted EPS was -$2.38 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did MBX Biosciences generate in fiscal 2025?
MBX Biosciences generated -$81.9M of free cash flow in fiscal 2025.
What was MBX Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), MBX Biosciences reported revenue of $0.
How many shares of MBX Biosciences are outstanding?
MBX Biosciences reported a weighted average of 47.7 million basic shares outstanding in 2026 Q2.
What is MBX Biosciences' market cap?
Based on its latest closing price, MBX Biosciences (MBX) has a market capitalization of about $2.34B.
When does MBX Biosciences' fiscal year end?
MBX Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is MBX Biosciences headquartered?
MBX Biosciences lists its business address in Carmel, Indiana in its SEC filings.